Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT04018027 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

401

Enrollment

INDUSTRY

Sponsor class

Conditions

Pruritus
Atopic Dermatitis

Interventions

DRUG: difelikefalin 0.25 mg
DRUG: difelikefalin 0.5 mg
DRUG: difelikefalin 1.0 mg
DRUG: Placebo

Sponsor

Cara Therapeutics, Inc.